Global Postmenopausal Osteoporosis Market, by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab among Others)), by Route of Administration (Oral, Intravenous Route, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4,547.8 Million in 2022 and is expected to exhibit a CAGR of 4.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The key players in the market are focusing on product launches to strengthen their market presence in the global postmenopausal osteoporosis market, which is expected to drive the market growth over the forecast period. For instance, on July 15, 2022, Chugai Pharmaceutical Co., Ltd. is a pharmaceutical drug manufacturer operating in Japan has announced that its wholly-owned group company in China, Chugai Pharma China Co., Ltd., launched Edirol (generic name: eldecalcitol) in China for the treatment of postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative created by Chugai. The product obtained regulatory approval from the China National Medical Products Administration (NMPA) in December 2020.
Global Postmenopausal Osteoporosis Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others are facing problems with the transportation of drugs from one place to another.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.
The COVID-19 pandemic had a negative impact on the osteoporosis treatment market, owing to disruption of fracture liaison services. Moreover, during the pandemic, hospitals and private health clinics cancelled non-emergency procedures and office visits, and several U.S. citizens postponed care to stop the spread of the virus, which further affected the osteoporosis market. A Morbidity and Mortality Weekly Report by the Centers for Disease Control and Prevention (CDC) acknowledged that by the end of June 2020, an estimated 41% of adults in the U.S. had delayed or avoided medical care including urgent or emergency care (12%) and routine care (32%) because of concerns or changes in healthcare delivery related to COVID-19.
Global Postmenopausal Osteoporosis Market: Key Developments
On August 25, 2022, Alvotech, a global biotech company specializing in the development and manufacture of biosimilars medicines, announced the initiation of a confirmatory patient study for AVT03 (denosumab), a biosimilar candidate for Prolia and Xgeva. The objective of the study is to demonstrate the clinical similarity of AVT03 to Prolia in terms of efficacy, safety, immunogenicity, and pharmacokinetics in postmenopausal women with osteoporosis.
Browse 58 Market Data Tables and 53 Figures spread through 339 Pages and in-depth TOC on “Global Postmenopausal Osteoporosis Market”- Forecast to 2030, by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab among Others)), by Route of Administration (Oral, Intravenous Route, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/postmenopausal-osteoporosis-market-5479
Key Takeaways of the Global Postmenopausal Osteoporosis Market:
- The global postmenopausal osteoporosis market is expected to exhibit a CAGR of 4.4% during the forecast period. The increasing research and development activities by research organizations for postmenopausal osteoporosis is expected to drive the segment growth over the forecast period. For instance, on August 9, 2022, eLife, a non-profit organization inspired by research funders and led by scientists, announced that scientists have developed a new mathematical model that may help clinicians decide on the best combination of osteoporosis medications for patients and the order in which they should be taken. The model may help improve outcomes for patients with postmenopausal osteoporosis and reduce the risks of side effects by helping physicians build more personalized treatment regimes.
- Among route of administration, the Oral segment is estimated to hold a dominant position in the global postmenopausal osteoporosis market over the forecast period. For instance, on March 10, 2022, an article published by The National Center for Biotechnology Information (NCBI) stated that the pooled prevalence of osteoporosis in the spine and the femur bone was 31.99% and 15.93%, respectively. Also, the prevalence of osteopenia in the spine and the femur bone was 22.48% and 39.88%, respectively.
- Among regions, North America is expected to be the most dominant region in the global postmenopausal osteoporosis market, owing to increasing research and development activities by research For instance, on June 1, 2022, The Foundation for the National Institutes of Health (FNIH), U.S. announced that the U.S. Food and Drug Administration (FDA) Biomarkers Qualification Program accepted a qualification plan to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs. The qualification plan submission was an accomplishment of the Study to Advance BMD as a Regulatory Endpoint (SABRE), or Bone Quality Project, which is managed by the FNIH and supported financially through a partnership with the American Society for Bone and Mineral Research (ASBMR).
- Major players operating in the global postmenopausal osteoporosis market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
